Report published by PatientView, June 2016
If you would like more information, or would like to get hold of this report, please use contact details below
London, Friday, 17th June 2016. This report is based on the findings of a PatientView November 2015-January 2016 survey exploring the views of 58 Latin American patient groups—from Argentina, Brazil, Chile, Colombia, Guatemala, Mexico, Nicaragua, Paraguay, Peru, Puerto Rico, and Venezuela.
The report provides feedback (from the perspective of these patient groups) on the corporate reputation of the pharma industry during 2015, as well as on the performance of 13 pharma companies trading in Latin America at six key indicators that influence corporate reputation. Results are compared with those of other countries/geographic regions from the 2015 survey.
For the purposes of this report, the phrase ‘corporate reputation’ is defined as the extent to which pharma companies are meeting the expectations of patients and patient groups.
The six indicators of corporate reputation:
The 13 companies analysed:
AbbVie I AstraZeneca I Bayer I Boehringer Ingelheim I Bristol-Myers Squibb I GSK I Janssen I Lilly I Merck & Co I Novartis I Pfizer I Roche I Sanofi
“Los medicamentos son muy caros, estamos siempre buscando la manera en que nuestro grupo de beneficiarios puedan tener acceso al tratamiento, sin interrupción.”
—Regional Mexico-based patient group specialising in chronic disease in general
“Existe contacto con médicos pero no hay programas para los pacientes.”
—National Columbia-based patient group specialising in epilepsy
INDUSTRY-WIDE FINDINGS
The 58 patient groups based in Latin America and responding to the 2015 ‘Corporate Reputation of Pharma’ survey were significantly more positive about the pharma industry’s corporate reputation than patient groups from other parts of the world in 2015 (with the possible exception of patient groups from Eastern Europe).
In 2015, the pharma industry received positive responses from the 58 respondent Latam patient groups for several of its key activities (more positive than from patient groups in most other countries and regions of the world). Results include:
HOWEVER, PATIENT GROUPS IN LATIN AMERICA DO BELIEVE THAT PHARMA NEEDS TO IMPROVE IN SOME SUBJECT AREAS ...
When asked by the ‘Corporate-Reputation’ survey in 2015 to identify the single most-important single policy a pharma company can adopt to improve its corporate reputation, Latam patient groups nominated: having a fair pricing policy.
HOW INDIVIDUAL PHARMA COMPANIES PERFORMED FOR CORPORATE REPUTATION IN LATIN AMERICA IN 2015
The table shows the 13 pharma companies ranked according to their corporate reputation, as measured by Latam patient groups in 2015, versus the same companies' overall rankings among patient groups worldwide in 2015 (the latter a ranking out of 48 companies).
END OF STATEMENT
PatientView is a UK-based research organisation that consults closely with patient groups, and publicises the work of the patient-advocacy movement.